BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36427906)

  • 1. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
    Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
    Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
    Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
    Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
    Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
    Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
    Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graded RhoA GTPase Expression in Treg Cells Distinguishes Tumor Immunity From Autoimmunity.
    Kalim KW; Yang JQ; Modur V; Nguyen P; Li Y; Zheng Y; Guo F
    Front Immunol; 2021; 12():726393. PubMed ID: 34721389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.
    Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A
    Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.
    Fabian KP; Malamas AS; Padget MR; Solocinski K; Wolfson B; Fujii R; Abdul Sater H; Schlom J; Hodge JW
    Cancer Immunol Res; 2021 Feb; 9(2):239-252. PubMed ID: 33355290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
    Aristin Revilla S; Kranenburg O; Coffer PJ
    Front Immunol; 2022; 13():903564. PubMed ID: 35874729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of Cancer by Targeting Regulatory T cells.
    Chen BJ; Zhao JW; Zhang DH; Zheng AH; Wu GQ
    Int Immunopharmacol; 2022 Mar; 104():108469. PubMed ID: 35008005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
    Li Y; Wang Z; Lin H; Wang L; Chen X; Liu Q; Zuo Q; Hu J; Wang H; Guo J; Xie L; Tang J; Li Z; Hu L; Xu L; Zhou X; Ye L; Huang Q; Xu L
    Front Immunol; 2020; 11():806. PubMed ID: 32477338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
    Wang H; Franco F; Tsui YC; Xie X; Trefny MP; Zappasodi R; Mohmood SR; Fernández-García J; Tsai CH; Schulze I; Picard F; Meylan E; Silverstein R; Goldberg I; Fendt SM; Wolchok JD; Merghoub T; Jandus C; Zippelius A; Ho PC
    Nat Immunol; 2020 Mar; 21(3):298-308. PubMed ID: 32066953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
    Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
    Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
    Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
    Ohue Y; Nishikawa H
    Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.